SERTRALINE HYDROCHLORIDE - Generic Drug Details

What are the generic sources for sertraline hydrochloride and what is the scope of freedom to operate?

Sertraline hydrochloride is the generic ingredient in two branded drugs marketed by Almatica, Amneal, Appco, Novitium Pharma, Umedica, Zenara, Zydus Lifesciences, Aurobindo Pharma, Ranbaxy Labs Ltd, Strides Pharma, Viatris, Accord Hlthcare, Ascent Pharms Inc, Chartwell Molecular, Granules, Heritage, Heritage Pharma Avet, Hikma Pharms, Invagen Pharms, Ivax Sub Teva Pharms, Lupin, Mylan Pharms Inc, Oxford Pharms, Pharmaco, Pharmobedient, Quagen, Reyoung, Sciegen Pharms, Sun Pharm Inds (in), Sun Pharm Inds Ltd, Torrent Pharms, Tp Anda Holdings, and Zydus, and is included in thirty-nine NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty drug master file entries for sertraline hydrochloride. Fifty-two suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for SERTRALINE HYDROCHLORIDE

US Patents:	0
Tradenames:	2
Applicants:	33
NDAs:	39
Drug Master File Entries:	20
Finished Product Suppliers / Packagers:	52
Raw Ingredient (Bulk) Api Vendors:	147
Clinical Trials:	340
What excipients (inactive ingredients) are in SERTRALINE HYDROCHLORIDE?	SERTRALINE HYDROCHLORIDE excipients list
DailyMed Link:	SERTRALINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for SERTRALINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Stanford University	PHASE2
Lakshmi N Yatham	PHASE3
South Valley University	NA

See all SERTRALINE HYDROCHLORIDE clinical trials

Generic filers with tentative approvals for SERTRALINE HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		EQ 100MG BASE	TABLET;ORAL
		EQ 50MG BASE	TABLET;ORAL
		EQ 25MG BASE	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for SERTRALINE HYDROCHLORIDE

Drug Class	Serotonin Reuptake Inhibitor
Mechanism of Action	Cytochrome P450 2D6 Inhibitors Serotonin Uptake Inhibitors

Medical Subject Heading (MeSH) Categories for SERTRALINE HYDROCHLORIDE

Antidepressive Agents

Serotonin Uptake Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for SERTRALINE HYDROCHLORIDE

N06AB	Selective serotonin reuptake inhibitors
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for SERTRALINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZOLOFT	Tablets	sertraline hydrochloride	150 mg and 200 mg	019839	1	2005-11-09
ZOLOFT	Oral Concentrate	sertraline hydrochloride	20 mg/mL	020990	1	2003-12-09

US Patents and Regulatory Information for SERTRALINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Heritage Pharma Avet	SERTRALINE HYDROCHLORIDE	sertraline hydrochloride	TABLET;ORAL	077345-002	Feb 6, 2007		DISCN	No	No
Oxford Pharms	SERTRALINE HYDROCHLORIDE	sertraline hydrochloride	TABLET;ORAL	078175-002	Jul 21, 2010	AB	RX	No	No
Zenara	SERTRALINE HYDROCHLORIDE	sertraline hydrochloride	CAPSULE;ORAL	218853-002	Jul 16, 2025	AB	RX	No	No
Zydus	SERTRALINE HYDROCHLORIDE	sertraline hydrochloride	TABLET;ORAL	077106-003	Feb 6, 2007		DISCN	No	No
Appco	SERTRALINE HYDROCHLORIDE	sertraline hydrochloride	TABLET;ORAL	077713-001	Feb 6, 2007		DISCN	No	No

Expired US Patents for SERTRALINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	ZOLOFT	sertraline hydrochloride	TABLET;ORAL	019839-001	Dec 30, 1991	5,789,449
Viatris	ZOLOFT	sertraline hydrochloride	CONCENTRATE;ORAL	020990-001	Dec 7, 1999	5,789,449
Viatris	ZOLOFT	sertraline hydrochloride	CONCENTRATE;ORAL	020990-001	Dec 7, 1999	4,940,731
Viatris	ZOLOFT	sertraline hydrochloride	TABLET;ORAL	019839-003	Dec 30, 1991	5,744,501
Viatris	ZOLOFT	sertraline hydrochloride	TABLET;ORAL	019839-004	Dec 30, 1991	5,744,501

Market dynamics and financial trajectory for SERTRALINE HYDROCHLORIDE

Last updated: May 6, 2026

What does the market look like for sertraline hydrochloride?

Sertraline hydrochloride is a large-volume, off-patent antidepressant active ingredient used across branded and generic products. Its market dynamics are dominated by (1) patent and market exclusivity expiry in major jurisdictions, (2) sustained generic adoption, and (3) ongoing demand resilience driven by chronic use patterns in depression and related indications.

Demand profile and pricing pressure

• Sertraline is a daily, chronic-treatment medicine. That stabilizes prescription volumes relative to episodic therapies.
• Generic substitution compresses net prices and increases manufacturing-driven competition.
• The market typically shifts from brand-led to generic-led composition as exclusivities roll off, with subsequent price competition concentrated among established generics.

Commercial implications

• Growth comes primarily from volume expansion, guideline-driven prescribing, and formulary position changes, not from premium pricing.
• Margin structure depends on manufacturing scale, cost of API sourcing, and compliance cost discipline rather than differentiation.

How do lifecycle and exclusivity dynamics shape financial trajectory?

Sertraline has moved through the typical lifecycle pattern for a first-line, widely adopted SSRI: initial brand exclusivity, then multi-jurisdiction generic entry that drives price erosion, followed by consolidation around cost-efficient manufacturers.

Lifecycle effects on revenue

• Early phase: Brand revenue leads, supported by exclusivity.
• Post-exclusivity: Generic entry reduces market prices quickly in countries where substitution is permitted.
• Later phase: Market stabilizes at lower ASP levels, with winners capturing share through supply reliability and distribution reach.

Financial trajectory pattern (typical for sertraline at this stage)

• Revenue: tends to grow slowly or flatten in nominal terms; may rise in volume but is offset by price compression.
• Gross margin: contracts as pricing falls; stabilizes when manufacturing economics and scale create a cost advantage.
• Cash flow: improves for scale producers as inventory turns remain steady due to constant demand.

What market forces drive pricing and volume for generic sertraline?

Generic sertraline dynamics are a function of competition intensity and regulatory speed-to-market.

Key drivers

1. Generic substitution rules and payer behavior: Formularies and pharmacy benefit managers determine switching pace. Competitive bidding and preferred generic lists accelerate volume migration.
2. Supply chain reliability: Shortages can create temporary price rebounds. Stable production dampens volatility.
3. API and dosage-form manufacturing costs: Tablet and liquid strengths compete largely on total cost per dose and compliance throughput.
4. International market fragmentation: Pricing varies by country based on tendering systems, reimbursement caps, and local generic intensity.

Competitive structure

• The market is supplied by multiple generic manufacturers across dosage strengths and packaging configurations.
• Differentiation shifts from “therapeutic uniqueness” to reliability, lead times, and distribution coverage.

How do major indications influence commercial stability?

Sertraline is prescribed for depression and anxiety-related disorders, including conditions where long-term treatment adherence creates predictable baseline demand.

Why this matters financially

• Chronic or maintenance therapy reduces dependence on seasonal or one-time use.
• Prescriber familiarity supports continued prescribing even as prices compress.
• Uptake is influenced by SSRI guideline norms and switching behavior from other antidepressants.

Implication for revenue resilience

• Expect less demand volatility than oncology or specialty chronic pipeline drugs.
• Most financial upside comes from share gains, not from major new therapeutic breakthroughs.

What are the principal legal and regulatory factors affecting market share?

For established generics, market share shifts are typically triggered by:

• Launch timing in specific geographies after exclusivity expiry.
• Regulatory compliance outcomes that affect ability to supply.
• Product-specific issues such as labeling changes, formulation adjustments, or distribution constraints.

Observed market behavior for off-patent drugs

• Legal uncertainty is usually concentrated earlier in the lifecycle (pre- and post-expiry).
• After generic establishment, ongoing impact is generally product-supply and compliance oriented rather than fundamental molecule novelty.

How do financial metrics usually evolve post-generic entry?

For sertraline, the market’s financial trajectory is best modeled as a conversion from high-margin branded revenue to lower-margin generic revenue.

Expected progression

• ASP decline: sharp drop at launch of multiple generic entrants, then slower erosion.
• Volume share rotation: winners typically secure preferred status and sustain consistent supply.
• Earnings pressure: operating income becomes more sensitive to manufacturing efficiency and working capital management.
• Industry consolidation: weak suppliers exit or reduce capacity, leaving a smaller set of scale players with stronger pricing power.

Where does revenue growth come from at this stage?

With the molecule established and generics entrenched, growth sources narrow.

Primary sources

• Geographic expansion: penetration of additional markets where reimbursement and substitution rules differ.
• Formulary updates: preferred positioning changes among competing SSRIs.
• Dose-strength and formulation coverage: broader packaging, pharmacy-friendly configurations, and reliable availability.

Secondary sources

• Switching from other SSRIs: driven by tolerability and prescriber/patient experience.
• Care pathways: primary care and psychiatry workflows influence prescription allocation across SSRIs.

What is the likely market-size and revenue profile directionally?

Sertraline is one of the highest-volume antidepressants globally, and the generic market tends to scale with population size and diagnosis rates. Financial trajectory typically reflects:

• rising total prescriptions across regions,
• falling or capped price per unit,
• net revenue that grows slower than units, or flattens depending on intensity of generic competition.

Directional conclusion

• The market is mature and price-competitive.
• The revenue line is stable in units, but structurally pressured in price.

How do payer and procurement dynamics translate into financial outcomes?

Payers and pharmacy channels manage cost through:

• preferred drug lists,
• competitive contracting,
• pharmacy brand substitution incentives.

Effects on financials

• Net revenue tracks tender outcomes and preferred-list inclusion.
• Gross margin depends on how quickly suppliers can reprice and maintain supply at contracted terms.
• Marketing spend usually stays limited relative to volume-driven sales.

What investment and R&D implications follow from these market dynamics?

For an established molecule like sertraline hydrochloride:

• R&D differentiation is usually not about inventing new efficacy, but about reformulation, improved delivery, stability, and line extensions that can win market access or reduce manufacturing costs.
• Investment return is tied to the ability to operate at low unit cost, secure supply continuity, and obtain advantageous distribution terms.

Key takeaways

• Sertraline hydrochloride is a mature, high-volume SSRI market dominated by generic competition and chronic-use demand.
• Financial trajectory typically follows: branded peak revenue, then price compression after exclusivity expiry, then stable unit demand with margin pressure.
• Growth drivers shift from innovation to formulary positioning, geographic penetration, supply reliability, and manufacturing scale.
• Payer procurement practices determine net revenue more than product-specific differentiation once generics dominate.

FAQs

1) Does sertraline’s chronic use make demand more stable than acute therapies?

Yes. Treatment patterns in depression and related indications support steady baseline prescription volumes, even as prices compress in generic markets.

2) What typically happens to revenue after generic entry?

Revenue can remain stable in unit terms while nominal revenue often flattens or grows slowly because average pricing drops and contracting reduces net prices.

3) What determines which generic manufacturers capture share?

Scale manufacturing economics, consistent supply, regulatory/compliance performance, and preferred-list or tender wins.

4) Are there meaningful upside opportunities for differentiation?

Differentiation tends to be operational (cost, supply, formulation convenience) rather than clinical novelty once the active ingredient is off-patent.

5) How do payer formularies affect financial outcomes?

Formularies and pharmacy benefit contracts drive substitution speed and net realized pricing, often overriding brand-level considerations once multiple generics compete.

---

References

[1] U.S. National Library of Medicine. Sertraline hydrochloride. MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a697010.html
[2] DailyMed. Zoloft (sertraline hydrochloride) prescribing information. https://dailymed.nlm.nih.gov/dailymed/
[3] World Health Organization. Antidepressant medicines: information and use. https://www.who.int/
[4] IMS Institute for Healthcare Informatics. Medicines use and spending trends (global market context). https://www.iqvia.com/insights/the-iqvia-institute